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Basal Cell Carcinoma-Like Epidermal Changes Overlying
Dermatofibromas Often Reveal Loss of Heterozygosity in the
PTCH Gene
To the Editor:
Dermatofibromas (DF) are benign dermal tumors that frequently
exhibit a spectrum of overlying epidermal acanthosis. Mild acanthosis
is the most common finding. Occasionally, significant basaloid prolif-
eration is observed, and rarely, follicular and even basal cell carcinoma
(BCC)-like changes may be seen. Whether the latter represent actual
BCCor are instead a reactive hyperplasia, perhapswith differentiation
towards follicular structures, has been disputed.
The patch (PTCH) gene is a developmental gene involved with
spacial organization in the Drosophilia fruit fly and mice, and it is
now known to also function as a tumor suppressor gene in human
tumors. Germ-line mutations in PTCH have been detected in almost
all cases of the nevoid basal cell carcinoma syndrome, and somatic
mutations in PTCH are found in over one-third of all sporadic basal
cell carcinomas (Gailani and Bale, 1997). It has been suggested that
PTCH may even represent a ‘‘gatekeeper gene’’ for BCC develop-
ment (Sidransky, 1996); however, while PTCH mutations were
originally thought to be present exclusively in BCC, a recent study
of trichoepitheliomas, which are benign follicular neoplasms that
may bear some histologic similarities to BCC, found that two of
nine specimens also contained mutations in PTCH (Vorechovsky
et al, 1997).
We hypothesized that the follicular or BCC-like changes
overlying DF might represent early clonal proliferations or even
precursors to BCC. Based on Knudson’s hypothesis, loss of
heterozygosity (LOH) often represents the second step in tumor
suppressor gene inactivation (Knudson, 1971). Because PTCH inac-
tivation occurs frequently in BCC development, we analyzed five
DF with follicular or BCC-like histologic changes (Fig 1) and five
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DF with mild acanthosis (data not shown) for evidence of LOH at
the PTCH locus. The epithelial portion of each histologic specimen
was carefully microdissected off of its slide using a fine needle under
an inverted microscope. The tissue was then deparaffinized in xylene
and the DNA was extracted (Nawroz et al, 1994). Normal and
tumor DNA was analyzed for LOH after polymerase chain reaction
amplification of polymorphic dinucleotide repeat sequences. We
chose four markers at the PTCH locus for microsatellite analysis
(Fig2a). These markers are highly polymorphic and one exists within
the PTCH gene itself. Polymerase chain reaction products were
separated by electrophoresis followed by autoradiography. For
informative cases allelic loss was scored and confirmed by two inde-
pendent observers (P.L. and D.S.). Loss was scored if the intensity of
one allele was at least 30% reduced in the tumor compared with the
normal DNA.
Polymerase chain reaction-based microsatellite analysis revealed
LOH of the PTCH locus in three of the five specimens with follicular
or BCC-like changes (Fig 2b) and in none of the five specimens with
mild acanthosis (data not shown). In each positive case, LOH was
present in all informative markers, confirming loss of at least one
PTCH allele in each of the samples. LOH clearly indicates the
presence of a clonal process in the epidermis overlying these dermal
tumors. Any contamination of sample tissues by normal cells would
only have the effect of underrepresenting the presence of PTCH
mutations in our samples, by producing false negative but not false
positive results.
This evidence indicates clonality in what is historically described
as a reactive hyperplastic process. Moreover, the presence of LOH at
the PTCH locus in these BCC-like basaloid proliferations is
consistent with, but not diagnostic of, PTCH inactivation and frank
BCC. Because PTCH mutations and LOH at the PTCH locus
have been found in another benign follicular epidermal neoplasm,
trichoepithelioma (Vorechovsky et al, 1997), the presence of PTCH
mutations in our specimens cannot differentiate between follicular
or BCC-like changes and true BCC.
In summary, we have established the presence of a clonal prolifera-
tion, probably secondary to PTCH inactivation, in a majority of DF
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Figure 1. Epidermal proliferative changes overlying dermato-
fibromas. (a) Acanthosis with occasional immature follicles and sebaceous
glands is commonly seen. (b) In rare cases, changes resemble basal cell
carcinoma. (c) Higher magnification of (b) reveals crowding of the basal
layer, peripheral palisading of basal epidermal nuclei (arrow), mitotic activity,
and stromal retraction identical to that seen in basal cell carcinoma. Scale
bar: (a, b) 104 µm; (c) 52 µm.
with extensive overlying epidermal basaloid proliferation. In the
remaining two specimens, LOH may have been obscured by normal
cell contamination, or PTCH inactivation may occur by small intra-
genic mutations of both PTCH alleles without LOH. Sequence
Figure 2. LOH on chromosomal arm 9q in DF. (a) Four microsatellite
markers were used. (b) LOH analysis on chromosomal arm 9q for two
cases of DF. Representative DF with BCC or follicle-like epidermal
basaloid proliferation (T) and corresponding normal tissue (N) are shown
for microsatellite marker D9S280. The lost allele is indicated by the arrows.
Case 3 demonstrates loss of the bottom allele and case 4 of the top allele.
See text for details.
analysis of the remaining allele remains to be done to formally demon-
strate PTCH inactivation in these lesions. It appears likely that PTCH
inactivation develops in a number of cutaneous neoplasms with
basaloid proliferation in addition to BCC.
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